Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Deals

Fosun Pharma Rumored to Fully Acquire Subsidiary Henlius Pharmaceutical, Shares Suspended

Fineline Cube May 30, 2024

Rumors are circulating, as reported by Bloomberg citing insiders, that Shanghai Fosun Pharmaceutical (Group) Co.,...

Company Drug

Amgen’s Bkemv Becomes First Biosimilar to Challenge AstraZeneca’s Soliris with FDA Approval

Fineline Cube May 30, 2024

Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company, has been granted regulatory approval by the...

Company Drug

Full-Life Technologies Receives FDA Green Light for ²²⁵Ac-FL-020 Clinical Study in mCRPC

Fineline Cube May 30, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company Deals Medical Device

Jiangxi Rimag Group Sets IPO Price Range for Hong Kong Debut, Aims to Raise Up to USD 2.15 per Share

Fineline Cube May 30, 2024

Jiangxi Rimag Group Co., Ltd, a leading medical imaging services provider based in China, has...

Company Deals

IVD Medical Holding Ltd Enters Non-Binding MoU with Chinese Chemiluminescence IVD Company for Potential Collaboration

Fineline Cube May 30, 2024

IVD Medical Holding Ltd (HKG: 1931), a leading in vitro diagnostic (IVD) company based in...

Company Deals

BMS Strikes Deal with Prothena for Potential Disease-Modifying Neurology Drug PRX019

Fineline Cube May 30, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has executed an exclusive global licensing agreement with Prothena...

Company Medical Device

Sino Medical Sciences’ Innovative Drug-Coated Stent System Accepted for NMPA Review

Fineline Cube May 29, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), a China-based medical technology company, has announced that...

Company Deals

Gilead Partners with Cartography Biosciences to Develop Therapies for Triple-Negative Breast Cancer

Fineline Cube May 29, 2024

Gilead Sciences (NASDAQ: GILD) has entered into a collaboration agreement with Cartography Biosciences, a US-based...

Company Deals

Sanofi Partners with Bluecrux to Enhance Supply Chain with AI Technologies

Fineline Cube May 29, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, is enhancing its supply chain strategy with...

Company Deals

Bio-Thera Solutions Partners with STADA for European Commercialization of Golimumab Biosimilar

Fineline Cube May 29, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced a licensing...

Company Deals

Roche Extends Long-Standing Partnership with Hitachi High-Tech to Innovate Diagnostic Solutions

Fineline Cube May 29, 2024

Roche (SWX: RO), a major Swiss pharmaceutical company, has renewed its 46-year partnership with Japan’s...

Company Deals

Asahi Kasei Moves to Fully Acquire Swedish Rare Disease Biopharma Calliditas in All-Cash Deal

Fineline Cube May 29, 2024

Japan’s Asahi Kasei Corporation (TYO: 3407) has announced an all-cash offer to fully acquire the...

Company Drug

Alphamab Oncology’s KN046 Misses Primary Endpoint in Phase III Pancreatic Cancer Study

Fineline Cube May 29, 2024

Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has announced disappointing results from...

Company Deals

3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical

Fineline Cube May 29, 2024

3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement...

Policy / Regulatory

China Unveils Comprehensive Plan to Tackle Unhealthy Practices in Pharma and Healthcare

Fineline Cube May 28, 2024

The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...

Company Deals

ChemPartner and Meta Bright to Jointly Develop a Pharmaceutical and Biotech Hub in Malaysia

Fineline Cube May 28, 2024

ChemPartner Pharmatech Co., Ltd (SHE: 300149), a biopharmaceutical company based in China, and Meta Bright...

Company Drug

Boan Biotech’s Dulaglutide Biosimilar Accepted for Review by China’s CDE

Fineline Cube May 28, 2024

Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced that the Center...

Company Drug

Hinova Pharmaceuticals to Present Phase I Data for PROTAC Drug HP518 at ASCO 2024

Fineline Cube May 28, 2024

Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, is poised to present data...

Company Drug

Henlius Biotech’s Biosimilar Rituximab Receives First Overseas Marketing Approval from Peru

Fineline Cube May 28, 2024

Shanghai Henlius Biotech Co., Ltd (HKG: 2696), a biopharmaceutical company based in China, has announced...

Company Drug

Hotgen Biotech Receives FDA Approval to Begin Clinical Trials for Acute Myocardial Infarction Drug

Fineline Cube May 28, 2024

Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...

Posts pagination

1 … 396 397 398 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.